Nilandron (nilutamide tablets) — Cigna

Initial criteria

• Patient has a diagnosis of metastatic prostate cancer (Stage D2)
• Nilutamide is used concurrently with a luteinizing hormone-releasing hormone (LHRH) agonist (e.g., leuprolide, triptorelin, goserelin, histrelin)

Approval duration

1 year